Impact of intracoronary radiation on in-stent XXXX involving @entity75 .

@entity1 @entity75 @entity256 @entity3151 @entity299 @entity3201
The aim of this study was to compare 6-month clinical outcomes of @entity1 with in-stent @entity256 (ISR) involving the ostium treated with intracoronary radiation therapy (IRT) compared to placebo therapy, and also to nonostial lesions treated with IRT. Coronary interventions in @entity75 have a high rate of recurrence of @entity256 . The impact of IRT on ostial ISR has been inadequately characterized. We assessed @entity1 enrolled in gamma (192- @entity3201 ) and beta (90-yttrium, 32- @entity3151 ) radiation trials for ISR at the Washington Hospital Center. Of @entity1 receiving IRT, 105 (8%) @entity1 had ostial ISR and 1,289 (92%) @entity1 had nonostial ISR. Twenty-seven @entity1 had ostial ISR and received placebo therapy. Baseline demographic and angiographic and procedural details were similar, except ostial IRT @entity1 had a trend toward shorter lesions (15.4 +/- 10.8 vs. 24.1 +/- 12.2 mm; P < 0.001) and had a higher rate of saphenous vein graft disease (46% vs. 19%; P < 0.001) compared to nonostial IRT @entity1 . At 6 months, @entity75 treated with IRT for ISR had a reduced rate of @entity75 revascularization (TLR) compared to @entity75 treated with placebo (15% vs. 43%; P = 0.004). Outcomes at 6 months were similar for the ostial and nonostial IRT groups including TLR (15% vs. 14%; P = 0.80) and composite major adverse @entity299 (18% vs. 15%; P = 0.46). Intracoronary radiation therapy is effective for @entity75 and should be comfortably used for this challenging anatomic location.
